Any guesses for how long it's going to take to get back to $8.50? I give it 3 weeks.
This company is slowly turning into a capitalistic beast. In some ways, I am proud, and in others, I am disgusted. Like every entity or person that is soiled with money, it corrupts.
Looking forward to tomorrow's numbers. I am predicting a $2-3 million upside surprise. All of the sales staff have had a quarter back on "the street" to work on new customers and have excellent leads with all of the new PDL1 customer requests.
An interesting observation. I was reading the NEJM last evening, a study new therapies for aplastic anemia. Lot of pathology and flow cytometry used to characterize response rates, etc. Anyway, at the end of the paper the authors expressed thanks to Neogenomics, among others. The study drug is a Glaxo-Novartis product. So the pharmaceutical/clinical trials business is for real. Revenue growth has been anemic. And I was surprised at the really low margins for the PD-L1 test. But this is a formidable little company with world class technology, growing it's niche. It's a worthy investment. I think the European expansion is great idea, BTW, unlike some other posters. Both companies referenced in the study I mentioned are Europe based, for example.
I'm very disappointed in both top+bottom numbers and full year guidance. NEO managements should adjust their focus. Adding more senior positions does not make sense if it does not help growths and bringing added values to shareholders.
Interesting addition announced today. Bill Bonnelo is a "wired in" Investment guy.
X axis : Stocks Price Correlation Coefficient Y axis : Quantity of stocks May-2016 1,000 Day Parameter 2,830 NASDAQ Stocks Price Analysis This stock mode of correlation coefficient is -0.5 In other words, the correlation coefficient of the other stoc
Short Interest in NeoGenomics, Inc. (NEO) Expands By 45.4%
NeoGenomics, Inc. (NASDAQ:NEO) saw a significant growth in short interest in the month of February. As of February 28th, there was short interest totalling 6,098,955 shares, a growth of 45.4% from the February 15th total of 4,194,723 shares. Based on
Downside risk pretty much eliminated now that NEO has seen institutional ownership reached the lower limits of 58.80%. if you guys have questions you should ask goog. They often respond to my emails which is helpful.
We are trading in an "arbitrage" range, right at the strike price of the preferred shares that need to be retired. I'm guessing that we remain in this range until the co. does, in fact, retire the remaining shares that were part of the GE deal. I've seen this before and have seen share value unleashed when the overhang has been removed.